R4 Ballot #1 (Mixed Normative/Trial use)

This page is part of the FHIR Specification (v3.3.0: R4 Ballot 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4 R3

Medicationrequest0306.json

Pharmacy Work GroupMaturity Level: N/ABallot Status: InformativeCompartments: Encounter, Patient, Practitioner

Raw JSON (canonical form)

Oral Chemotherapy Order - Myleran - completed - with reasonCode

{
  "resourceType": "MedicationRequest",
  "id": "medrx0306",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: medrx0306</p><p><b>contained</b>: </p><p><b>identifier</b>: 12345689 (OFFICIAL)</p><p><b>status</b>: active</p><p><b>intent</b>: order</p><p><b>medication</b>: Myleran 2mg tablet. Generated Summary: id: med0304; Myleran 2mg tablet, film coated <span>(Details : {http://hl7.org/fhir/sid/ndc code '76388-713-25' = '76388-713-25', given as 'Myleran 2mg tablet, film coated'})</span></p><p><b>subject</b>: <a>Donald Duck</a></p><p><b>authoredOn</b>: 15/01/2015</p><p><b>requester</b>: <a>Patrick Pump</a></p><p><b>reasonCode</b>: Chronic myeloid Leukemia (disorder) <span>(Details : {SNOMED CT code '92818009' = 'Chronic myeloid leukemia', given as 'Chronic myeloid Leukemia (disorder)'})</span></p><p><b>dosageInstruction</b>: </p></div>"
  },
  "contained": [
    {
      "resourceType": "Medication",
      "id": "med0304",
      "code": {
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/ndc",
            "code": "76388-713-25",
            "display": "Myleran 2mg tablet, film coated"
          }
        ]
      }
    }
  ],
  "identifier": [
    {
      "use": "official",
      "system": "http://www.bmc.nl/portal/prescriptions",
      "value": "12345689"
    }
  ],
  "status": "active",
  "intent": "order",
  "medicationReference": {
    "reference": "#med0304",
    "display": "Myleran 2mg tablet"
  },
  "subject": {
    "reference": "Patient/pat1",
    "display": "Donald Duck"
  },
  "authoredOn": "2015-01-15",
  "requester": {
    "reference": "Practitioner/f007",
    "display": "Patrick Pump"
  },
  "reasonCode": [
    {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "92818009",
          "display": "Chronic myeloid Leukemia (disorder)"
        }
      ]
    }
  ],
  "dosageInstruction": [
    {
      "sequence": 1,
      "text": "6 mg PO daily for remission induction; adjust dosage to white blood cell (WBC) count.  With hold treatment if WBC is less than 15,000/µL; resume when WBC is greater than 50,000/µL",
      "timing": {
        "repeat": {
          "frequency": 1,
          "period": 1,
          "periodUnit": "d"
        }
      },
      "route": {
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "26643006",
            "display": "Oral route (qualifier value)"
          }
        ]
      },
      "doseAndRate": [
        {
          "type": {
            "coding": [
              {
                "system": "http://hl7.org/fhir/dose-rate-type",
                "code": "ordered",
                "display": "Ordered"
              }
            ]
          },
          "doseQuantity": {
            "value": 6,
            "unit": "mg",
            "system": "http://unitsofmeasure.org",
            "code": "mg"
          }
        }
      ]
    }
  ]
}

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.